Moderna, Inc. (NASDAQ:MRNA) Stake Boosted by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 16.6% in the 4th quarter, Holdings Channel reports. The firm owned 1,081,869 shares of the company’s stock after acquiring an additional 154,112 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Moderna were worth $107,592,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Douglas Lane & Associates LLC grew its holdings in shares of Moderna by 36.4% during the third quarter. Douglas Lane & Associates LLC now owns 355,177 shares of the company’s stock valued at $36,686,000 after purchasing an additional 94,810 shares during the last quarter. International Assets Investment Management LLC boosted its position in shares of Moderna by 6,528.9% during the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after buying an additional 381,808 shares during the period. ARK Investment Management LLC boosted its position in shares of Moderna by 81.7% during the third quarter. ARK Investment Management LLC now owns 259,838 shares of the company’s stock worth $26,839,000 after buying an additional 116,840 shares during the period. Kentucky Retirement Systems Insurance Trust Fund acquired a new position in shares of Moderna during the third quarter worth approximately $1,185,000. Finally, Invesco Ltd. boosted its position in shares of Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after buying an additional 517,683 shares during the period. 75.33% of the stock is owned by institutional investors.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the sale, the insider now directly owns 9,267 shares of the company’s stock, valued at approximately $917,896.35. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the sale, the insider now directly owns 9,267 shares of the company’s stock, valued at approximately $917,896.35. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $107.12, for a total transaction of $1,606,800.00. Following the sale, the director now directly owns 2,071,931 shares in the company, valued at $221,945,248.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 79,954 shares of company stock worth $8,407,976. Insiders own 15.20% of the company’s stock.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $103.79 on Wednesday. Moderna, Inc. has a one year low of $62.55 and a one year high of $156.75. The stock has a fifty day moving average of $100.03 and a 200-day moving average of $93.52. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. During the same quarter in the prior year, the firm earned $3.61 EPS. The company’s quarterly revenue was down 44.9% compared to the same quarter last year. Research analysts forecast that Moderna, Inc. will post -7.51 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on MRNA. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Canaccord Genuity Group upped their target price on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. Finally, HSBC restated a “reduce” rating and issued a $86.00 target price (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.